Sheppard Pratt Health System
14 clinical trials · Sponsor
◉ Watch Sheppard Pratt Health System
| Record | Firm | Date |
|---|---|---|
| The Safety and Efficacy of Psilocybin in Patients With Treatment-resistant Depression and Chronic Suicidal Ideation (NCT05220410) | Sheppard Pratt Health System | 2022-03-28 |
| Synbiotic Compound to Reduce Symptoms of Schizophrenia (NCT04226898) | Sheppard Pratt Health System | 2022-02-21 |
| The Safety and Efficacy of Psilocybin in Participants With Type 2 Bipolar Disorder (BP-II) Depression. (NCT04433845) | Sheppard Pratt Health System | 2021-03-01 |
| An Open Label Study of the Safety and Efficacy of Psilocybin in Participants With Treatment-Resistant Depression (P-TRD) (NCT04433858) | Sheppard Pratt Health System | 2021-03-01 |
| Probiotics to Prevent Relapse After Hospitalization for Bipolar Depression (NCT03349528) | Sheppard Pratt Health System | 2018-12-11 |
Track Sheppard Pratt Health System automatically
Every clearance here is in the API, with alerts when new ones post.